Search
- Sep 28, 2023
Harbinger Health’s Steve Hahn on the science of early cancer Dx after raising a $140M Series B
Steve Hahn describes how Harbinger Health is trying to catch the earliest signals of cancer, and how this information might be used.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A